Compare
Ultragenyx Pharmaceutical Inc. vs Kiniksa Pharmaceuticals International, plc vs Axsome Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
| Latest fiscal year | Ultragenyx Pharmaceutical Inc. RARE | Kiniksa Pharmaceuticals International, plc KNSA | Axsome Therapeutics, Inc. AXSM | Supernus Pharmaceuticals, Inc. SUPN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $673.00M | $677.56M | $638.50M | $718.95M |
| Revenue growth (YoY) | +20.2% | +60.1% | +65.5% | +8.6% |
| Gross margin | n/a | 88.5% (computed) | n/a | 89.6% (computed) |
| Operating margin | -79.5% | 11.4% | -26.1% | -8.7% |
| Net margin | -85.4% | 8.7% | -28.7% | -5.4% |
| Net income | -$575.00M | $59.01M | -$183.17M | -$38.55M |
| EPS (Diluted) | -$5.83 | $0.75 | -$3.68 | -$0.68 |
| Operating cash flow | -$466.00M | $137.99M | -$93.41M | $47.33M |
| Free cash flow | -$472.00M | $136.42M | -$93.89M | $45.99M |
| Cash & equivalents | $421.00M | $165.60M | $322.93M | $128.45M |
| Total assets | $1.53B | $763.63M | $689.80M | $1.45B |
| Total liabilities | $1.60B | $196.03M | $601.51M | $390.93M |
| Shareholders' equity | -$80.00M | $567.61M | $88.30M | $1.06B |
| Return on year-end equity | n/a | 10.4% | -207.5% | -3.6% |
| Shares outstanding | 96.60M | n/a | 50.88M | 57.46M |
Revenue, most recent five fiscal years
| Fiscal year | Ultragenyx Pharmaceutical Inc. | Kiniksa Pharmaceuticals International, plc | Axsome Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $673.00M Ended 2025-12-31 | $677.56M Ended 2025-12-31 | $638.50M Ended 2025-12-31 | $718.95M Ended 2025-12-31 |
| 1 year earlier | $560.00M Ended 2024-12-31 | $423.24M Ended 2024-12-31 | $385.69M Ended 2024-12-31 | $661.82M Ended 2024-12-31 |
| 2 years earlier | $434.00M Ended 2023-12-31 | $270.26M Ended 2023-12-31 | $270.60M Ended 2023-12-31 | $607.52M Ended 2023-12-31 |
| 3 years earlier | $363.33M Ended 2022-12-31 | $220.18M Ended 2022-12-31 | $50.04M Ended 2022-12-31 | $667.24M Ended 2022-12-31 |
| 4 years earlier | $351.41M Ended 2021-12-31 | $38.54M Ended 2021-12-31 | n/a | $579.77M Ended 2021-12-31 |